Friday, July 10, 2026

Drug profile · INN

acetophenazine maleate

acetophenazine maleate (TINDAL) is a dopamine d2 receptor antagonist. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — acetophenazine maleate
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

acetophenazine maleate (TINDAL) is a dopamine d2 receptor antagonist. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN acetophenazine maleate
Brand TINDAL
Mechanism Dopamine D2 receptor antagonist
Target D(2) dopamine receptor
Route ORAL
Formulation TABLET

Mechanism of action

Dopamine D2 receptor antagonist

Primary target: D(2) dopamine receptor

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. aripiprazole Nervous system (N05)
  2. brexpiprazole Nervous system (N05)
  3. cabergoline Dopamine D2 receptor agonist
  4. clozapine Serotonin 2a (5-HT2a) receptor antagonist
  5. fluphenazine decanoate Dopamine D2 receptor antagonist
  6. fluphenazine hydrochloride Dopamine D2 receptor antagonist

Frequently asked questions

What is acetophenazine maleate?

acetophenazine maleate (TINDAL) is a dopamine d2 receptor antagonist. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for acetophenazine maleate?

TINDAL is a marketed brand name for acetophenazine maleate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of acetophenazine maleate?

acetophenazine maleate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.